EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
- FDA
Related events
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- Alvotech submitted a regulatory application to the European Medicines Agency (EMA).
- PolyPid Ltd's product received FDA Priority Review and gained single authorization across EU states from the EMA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval supports NDA submission in Aurora.